Arterium established its R&D Centre
Arterium Corporation R&D Centre was opened in August.
The establishment of such Centre reflects the corporate strategy to improve its R&D facilities. The project took more than 10 months. The Centre has up-to-date facilities to conduct research and develop pharmaceutical products. More than 100 specialists of Analytical and Technical Labs of Arterium Corporation R&D Centre have already moved to their new workstations. Our Registration, Innovations and Clinical Trials Teams will join them in the future.
Arterium R&D Centres have a very important mission – they develop new products, accumulate evidence to support product launch, develop modern generics, improve marketed drugs to bring their quality in line with modern requirements. For example, Arterium has launched nearly 30 pharmaceutical products including modern antibiotics Mepenam, Gliteik, and Linezolidin. The Centre makes research and development in line with current good practices possible.
At a short meeting coincided with the Pharmacist’s Day and R&D Centre Opening Ceremony, Denys Gartsylov, Arterium Chief Executive Officer, said:
“Establishment of this R&D Centre is a great achievement for our Company. This R&D Centre is not merely walls and equipment but the people working here. More than 130 drugs are under development now. Considering all pharmaceutical forms and dosing, this means nearly 200 current projects. I would like to say thanks to all our team members for their commitment and passion in working for the Company and bringing our ideas into life. The location of our R&D Centre is symbolic for the Company. At the dawn of implementation of GMP standards in Ukraine, it was here where the good manufacturing practice was first introduced for blistering and packaging of pharmaceutical products. Today, the R&D Centre gives this facility a new lease of life. We hope that our R&D Centre will, as in the case with GMP, put a spin on the research and development sector in Ukraine”.
In implementing the R&D Centre Project, the design standards and requirements to technological processes based on R&D equipment have been taken into account. For some rooms, stronger GMP requirements are applied.
Arterium invested about UAH 13 million to the R&D Centre.
In 2013, Arterium spent UAH 46 million for research and development that is 18% higher than its R&D investments in 2012.
Arterium invites to its R&D projects experienced specialists with doctor’s degree who graduated from major international universities and have expertise in R&D for international pharmaceutical companies.